- Indications and Usage Anaerobic Bacterial Infections: Indicated for the treatment of infections caused by susceptible anaerobic bacteria.
- Dosage and Administration Administration Route: For intravenous infusion only. Dosage: Dosage varies by infection severity and patient condition; standard clinical regimens typically involve dilution in appropriate volumes for controlled infusion. Renal/Hepatic Impairment: In patients with severe renal impairment, the dosing interval should be extended. In patients with hepatic impairment, dose reduction may be necessary.
- Mechanism of Action DNA Damage: Morinidazole enters bacterial and protozoal cells and undergoes reduction of its nitro group by ferredoxin. Cytotoxic Effect: The resulting cytotoxic nitro radical intermediates disrupt the DNA of microbial cells, inhibiting nucleic acid synthesis and leading to cell death.
- Safety and Warnings Neurotoxicity: Peripheral neuropathy, seizures, encephalopathy, and aseptic meningitis may occur. The drug should be discontinued if abnormal neurological symptoms or signs appear. Disulfiram-like Reaction: The drug may interfere with alcohol metabolism. Patients should be warned against consuming alcohol during and shortly after treatment to avoid severe reactions. Hypersensitivity: Serious allergic reactions to nitroimidazole derivatives are possible.
- Adverse Reactions and Clinical Research Most Common Adverse Reactions: Gastrointestinal disorders (nausea, abdominal pain, metallic taste) and headache are frequent. Clinical Research: Clinical evidence supports its efficacy in treating intra-abdominal, gynecological, and soft tissue anaerobic infections.
- Drug Interactions Warfarin and Anticoagulants: Morinidazole can inhibit the metabolism of warfarin and other oral anticoagulants, potentially prolonging the prothrombin time and increasing bleeding risk. Cimetidine: May inhibit the metabolism of morinidazole, prolonging its serum half-life. Alcohol and Disulfiram: Concomitant use is contraindicated due to the risk of disulfiram-like reactions.
- Pharmaceutical Information Chemical Composition: Active ingredient: Morinidazole; Solvent: Sodium Chloride Injection. Appearance: Colorless or almost colorless clear liquid. Storage: Store in a well-closed container, protected from light.
Mailinda Morinidazole and Sodium Chloride Injection
Brand Name:迈灵达 ®（Mailinda®）
Generic Name: Morinidazole and Sodium Chloride
Strength: Per 100 mL bottle: Morinidazole 0.5 g, Sodium Chloride 0.9 g; 1 bottle per package
Manufacturer: Jiangsu Haosen Pharmaceutical Group Co., Ltd.
Marketing Authorization Holder: Jiangsu Haosen Pharmaceutical Group Co., Ltd.
Approval Date in China: April 10, 2014
Registration Number: 国药准字H20140022
Storage: Store in a cool and dark place, avoid freezing and direct sunlight. Refer to the full package insert for detailed storage specifications.
Price&Cost:Contact Us now for the best price of Morinidazole and Sodium Chloride（Mailinda）
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.